Therefore, Mezynski and colleagues, using several gastric cell lines, tested the anti-cancer properties of copanlisib (PI3K inhibitor) in combination with refametinib (MEK1/2 inhibitor) and an HER2 inhibitor. Here, PIK3CD is linked to cancer.